Ignite Creation Date:
2025-12-25 @ 2:36 AM
Ignite Modification Date:
2025-12-30 @ 10:15 PM
Study NCT ID:
NCT04675034
Status:
COMPLETED
Last Update Posted:
2025-02-10
First Post:
2020-11-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Canada', 'South Africa', 'United States']}, 'conditionBrowseModule': {'meshes': [{'id': 'D010003', 'term': 'Osteoarthritis'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'information.center@astrazeneca.com', 'phone': '+1-877-240-9479', 'title': 'Global Clinical Lead', 'organization': 'AstraZeneca Clinical Study Information Center'}, 'certainAgreement': {'otherDetails': 'AstraZeneca has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Concomitant medication and therapies data do not necessarily evaluate the safety and are therefore not considered as outcome measures in this study.'}}, 'adverseEventsModule': {'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.', 'eventGroups': [{'id': 'EG000', 'title': 'MEDI7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.', 'otherNumAtRisk': 70, 'deathsNumAtRisk': 70, 'otherNumAffected': 51, 'seriousNumAtRisk': 70, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG001', 'title': 'MEDI7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.', 'otherNumAtRisk': 68, 'deathsNumAtRisk': 68, 'otherNumAffected': 45, 'seriousNumAtRisk': 68, 'deathsNumAffected': 0, 'seriousNumAffected': 5}, {'id': 'EG002', 'title': 'MEDI7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.', 'otherNumAtRisk': 69, 'deathsNumAtRisk': 69, 'otherNumAffected': 54, 'seriousNumAtRisk': 69, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG003', 'title': 'MEDI7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.', 'otherNumAtRisk': 68, 'deathsNumAtRisk': 68, 'otherNumAffected': 51, 'seriousNumAtRisk': 68, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.', 'otherNumAtRisk': 69, 'deathsNumAtRisk': 69, 'otherNumAffected': 40, 'seriousNumAtRisk': 69, 'deathsNumAffected': 0, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Extrasystoles', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 11, 'numAffected': 9}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Periodontitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pulpitis dental', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Respiratory syncytial virus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Respiratory tract infection viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Mitral valve incompetence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Skin infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Accidental exposure to product', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Adverse event following immunisation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Animal bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Back injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Palpitations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Bone contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cartilage injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Chillblains', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Foot fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Head injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Joint injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Ligament sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Limb injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Muscle injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Muscle strain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Musculoskeletal injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Post procedural contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Post-traumatic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Procedural pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Skin injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Soft tissue injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tachycardia paroxysmal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tooth fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Activated partial thromboplastin time prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood folate decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood glucose increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood pressure increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Accessory spleen', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood uric acid increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'C-reactive protein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Coagulation factor increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Drug screen positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Electrocardiogram qt prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Electrocardiogram t wave inversion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Faecal calprotectin abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gamma-glutamyltransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Glycosylated haemoglobin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vascular malformation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Liver function test increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertriglyceridaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Type 2 diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vitamin d deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 6, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Ear congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 9, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Facet joint syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Intervertebral disc degeneration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Joint swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Limb discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Limb mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Muscle tightness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Muscular weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pain in jaw', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Plantar fasciitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Polymyalgia rheumatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rapidly progressive osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tympanic membrane perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rotator cuff syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Soft tissue disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Spinal osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Spinal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Subchondral insufficiency fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tendon disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tendon pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tendonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Trigger finger', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acrochordon', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Haemangioma of bone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Haemangioma of liver', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lipoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Seborrhoeic keratosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tumour ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Areflexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Burning sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vertigo positional', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Carpal tunnel syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cervical radiculopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Disturbance in attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dizziness postural', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 11, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Polyneuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Goitre', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Presyncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Resting tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Sensory loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Alcohol abuse', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Depressed mood', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Amaurosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Glycosuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Leukocyturia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Micturition urgency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Renal cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Conjunctival haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinary incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinary tract inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': "Bartholin's cyst", 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Benign prostatic hyperplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pelvic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Aphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Glaucoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dysphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Haemoptysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pleuritic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Productive cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pulmonary mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lacrimation increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dermal cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Miliaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Photopsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pustular psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rosacea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Skin lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertensive crisis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Orthostatic hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Peripheral coldness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Superficial vein prominence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vitreous floaters', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abdominal mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abdominal pain lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dental discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Diverticulum intestinal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Duodenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lymphadenopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Food poisoning', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastric ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastrointestinal inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hiatus hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Mesenteric panniculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Noninfective gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lymphopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Oesophageal stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Oesophagitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tongue discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Feeling hot', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site bruising', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 10, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site induration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 7, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 7, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Malaise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Peripheral swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Temperature regulation disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Thirst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cholestasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatic lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatic steatosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatomegaly', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertransaminasaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Allergy to arthropod sting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Drug hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Seasonal allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Type iv hypersensitivity reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acarodermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Covid-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 16, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 12, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 8, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Ear infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Ear infection fungal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Epstein-barr virus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fungal skin infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Furuncle', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Infective exacerbation of chronic obstructive airways disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}], 'seriousEvents': [{'term': 'Multiple injuries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Splenic rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Traumatic renal injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Liver function test abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Arthritis reactive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastrointestinal carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Ovarian neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Loss of bladder sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Benign prostatic hyperplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acute respiratory distress syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Henoch-schonlein purpura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Large intestine polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Covid-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cardiovascular insufficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 70, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 68, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 69, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Weekly Average of Daily Numerical Rating Scale (NRS) Pain Score to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.19', 'spread': '2.243', 'groupId': 'OG000'}, {'value': '-3.00', 'spread': '2.342', 'groupId': 'OG001'}, {'value': '-2.83', 'spread': '2.522', 'groupId': 'OG002'}, {'value': '-2.81', 'spread': '2.835', 'groupId': 'OG003'}, {'value': '-2.35', 'spread': '2.364', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.360', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Combined estimate for LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.15', 'ciLowerLimit': '-0.968', 'ciUpperLimit': '0.670', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.416', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Least Square (LS) mean and treatment group difference with associated 95% confidence intervals (CIs) are modelled using ANCOVA on imputed data.'}, {'pValue': '0.029', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Combined estimate for LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.80', 'ciLowerLimit': '-1.619', 'ciUpperLimit': '0.027', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.418', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Least Square mean and treatment group difference with associated 95% CIs are modelled using ANCOVA on imputed data.'}, {'pValue': '0.026', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Combined estimate for LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.80', 'ciLowerLimit': '-1.618', 'ciUpperLimit': '0.009', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.413', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Least Square mean and treatment group difference with associated 95% CIs are modelled using ANCOVA on imputed data.'}, {'pValue': '0.083', 'groupIds': ['OG003', 'OG004'], 'paramType': 'Combined estimate for LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.59', 'ciLowerLimit': '-1.423', 'ciUpperLimit': '0.245', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.424', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Least Square mean and treatment group difference with associated 95% CIs are modelled using ANCOVA on imputed data.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -7 to Day -1, inclusive) through Week 12', 'description': 'Change from baseline in weekly average of daily NRS pain score to Week 12 is reported. The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This was recorded on a daily basis at approximately the same time every morning via electronic patient recorded outcome (ePRO) diary. A two-step multiple imputation procedure was used to address missing post-baseline scores.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscale to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.88', 'spread': '2.047', 'groupId': 'OG000'}, {'value': '-2.88', 'spread': '2.407', 'groupId': 'OG001'}, {'value': '-2.62', 'spread': '2.305', 'groupId': 'OG002'}, {'value': '-2.57', 'spread': '2.992', 'groupId': 'OG003'}, {'value': '-2.62', 'spread': '2.558', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0 (Day 1; baseline) through Week 12', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to osteoarthritis (OA) in the target knee. Each question was scored on a NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Change from baseline in WOMAC pain subscale to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.", 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in WOMAC Physical Function Subscale to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.48', 'spread': '2.233', 'groupId': 'OG000'}, {'value': '-2.56', 'spread': '2.352', 'groupId': 'OG001'}, {'value': '-2.45', 'spread': '1.909', 'groupId': 'OG002'}, {'value': '-2.22', 'spread': '2.887', 'groupId': 'OG003'}, {'value': '-2.14', 'spread': '2.338', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0 (Day 1; baseline) through Week 12', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC physical function (PF) subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Change from baseline in WOMAC physical function to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.", 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.'}, {'type': 'SECONDARY', 'title': "Change From Baseline in Patient's Global Assessment (PGA) of OA to Week 12", 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.34', 'spread': '0.933', 'groupId': 'OG000'}, {'value': '-0.72', 'spread': '1.123', 'groupId': 'OG001'}, {'value': '-0.81', 'spread': '1.032', 'groupId': 'OG002'}, {'value': '-0.69', 'spread': '1.377', 'groupId': 'OG003'}, {'value': '-0.57', 'spread': '1.003', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 0 (Day 1; baseline) through Week 12', 'description': 'The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Change from baseline in PGA of OA to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in WOMAC Pain Subscale Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.32', 'spread': '1.501', 'groupId': 'OG000'}, {'value': '-1.79', 'spread': '1.988', 'groupId': 'OG001'}, {'value': '-1.58', 'spread': '1.571', 'groupId': 'OG002'}, {'value': '-1.88', 'spread': '1.953', 'groupId': 'OG003'}, {'value': '-1.30', 'spread': '1.968', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.62', 'spread': '1.635', 'groupId': 'OG000'}, {'value': '-2.33', 'spread': '2.230', 'groupId': 'OG001'}, {'value': '-2.41', 'spread': '1.939', 'groupId': 'OG002'}, {'value': '-2.60', 'spread': '2.077', 'groupId': 'OG003'}, {'value': '-2.08', 'spread': '2.000', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '56', 'groupId': 'OG003'}, {'value': '55', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.01', 'spread': '1.541', 'groupId': 'OG000'}, {'value': '-2.76', 'spread': '2.223', 'groupId': 'OG001'}, {'value': '-2.73', 'spread': '1.852', 'groupId': 'OG002'}, {'value': '-3.07', 'spread': '2.065', 'groupId': 'OG003'}, {'value': '-2.40', 'spread': '2.114', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.01', 'spread': '1.840', 'groupId': 'OG000'}, {'value': '-2.96', 'spread': '2.259', 'groupId': 'OG001'}, {'value': '-2.91', 'spread': '1.954', 'groupId': 'OG002'}, {'value': '-3.33', 'spread': '1.964', 'groupId': 'OG003'}, {'value': '-2.56', 'spread': '2.431', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.14', 'spread': '1.886', 'groupId': 'OG000'}, {'value': '-3.22', 'spread': '2.282', 'groupId': 'OG001'}, {'value': '-2.89', 'spread': '2.052', 'groupId': 'OG002'}, {'value': '-3.54', 'spread': '2.055', 'groupId': 'OG003'}, {'value': '-2.89', 'spread': '2.283', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.00', 'spread': '2.090', 'groupId': 'OG000'}, {'value': '-3.02', 'spread': '2.388', 'groupId': 'OG001'}, {'value': '-2.61', 'spread': '2.107', 'groupId': 'OG002'}, {'value': '-3.50', 'spread': '1.988', 'groupId': 'OG003'}, {'value': '-2.97', 'spread': '2.219', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to OA in the target knee. Each question was scored on an NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Change from baseline in WOMAC pain subscale to Weeks 2, 4,6, 8, 10, and 18 is reported.", 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in WOMAC PF Subscale Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.06', 'spread': '1.621', 'groupId': 'OG000'}, {'value': '-1.64', 'spread': '1.877', 'groupId': 'OG001'}, {'value': '-1.56', 'spread': '1.417', 'groupId': 'OG002'}, {'value': '-1.80', 'spread': '1.778', 'groupId': 'OG003'}, {'value': '-0.96', 'spread': '1.728', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.59', 'spread': '1.812', 'groupId': 'OG000'}, {'value': '-2.07', 'spread': '1.933', 'groupId': 'OG001'}, {'value': '-2.20', 'spread': '1.701', 'groupId': 'OG002'}, {'value': '-2.39', 'spread': '2.062', 'groupId': 'OG003'}, {'value': '-1.62', 'spread': '1.708', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '56', 'groupId': 'OG003'}, {'value': '55', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.77', 'spread': '1.670', 'groupId': 'OG000'}, {'value': '-2.43', 'spread': '1.946', 'groupId': 'OG001'}, {'value': '-2.43', 'spread': '1.436', 'groupId': 'OG002'}, {'value': '-2.71', 'spread': '2.001', 'groupId': 'OG003'}, {'value': '-1.92', 'spread': '1.945', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.64', 'spread': '1.856', 'groupId': 'OG000'}, {'value': '-2.82', 'spread': '1.960', 'groupId': 'OG001'}, {'value': '-2.68', 'spread': '1.792', 'groupId': 'OG002'}, {'value': '-3.06', 'spread': '1.858', 'groupId': 'OG003'}, {'value': '-2.06', 'spread': '2.114', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.74', 'spread': '1.994', 'groupId': 'OG000'}, {'value': '-2.85', 'spread': '1.944', 'groupId': 'OG001'}, {'value': '-2.65', 'spread': '1.671', 'groupId': 'OG002'}, {'value': '-3.30', 'spread': '1.979', 'groupId': 'OG003'}, {'value': '-2.26', 'spread': '2.063', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.55', 'spread': '2.267', 'groupId': 'OG000'}, {'value': '-2.71', 'spread': '2.141', 'groupId': 'OG001'}, {'value': '-2.37', 'spread': '1.722', 'groupId': 'OG002'}, {'value': '-3.17', 'spread': '1.812', 'groupId': 'OG003'}, {'value': '-2.24', 'spread': '1.810', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC PF subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Change from baseline in WOMAC physical function to Weeks 2, 4, 6, 8, 10, and 18 is reported.", 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in WOMAC Overall Score Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.11', 'spread': '1.546', 'groupId': 'OG000'}, {'value': '-1.71', 'spread': '1.836', 'groupId': 'OG001'}, {'value': '-1.58', 'spread': '1.343', 'groupId': 'OG002'}, {'value': '-1.88', 'spread': '1.735', 'groupId': 'OG003'}, {'value': '-1.04', 'spread': '1.695', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.66', 'spread': '1.706', 'groupId': 'OG000'}, {'value': '-2.14', 'spread': '1.958', 'groupId': 'OG001'}, {'value': '-2.25', 'spread': '1.667', 'groupId': 'OG002'}, {'value': '-2.45', 'spread': '2.000', 'groupId': 'OG003'}, {'value': '-1.74', 'spread': '1.671', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '57', 'groupId': 'OG003'}, {'value': '56', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.85', 'spread': '1.583', 'groupId': 'OG000'}, {'value': '-2.54', 'spread': '1.968', 'groupId': 'OG001'}, {'value': '-2.52', 'spread': '1.426', 'groupId': 'OG002'}, {'value': '-2.79', 'spread': '1.951', 'groupId': 'OG003'}, {'value': '-1.98', 'spread': '1.984', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.75', 'spread': '1.792', 'groupId': 'OG000'}, {'value': '-2.85', 'spread': '1.995', 'groupId': 'OG001'}, {'value': '-2.69', 'spread': '1.757', 'groupId': 'OG002'}, {'value': '-3.12', 'spread': '1.822', 'groupId': 'OG003'}, {'value': '-2.19', 'spread': '2.102', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.86', 'spread': '1.907', 'groupId': 'OG000'}, {'value': '-2.94', 'spread': '1.995', 'groupId': 'OG001'}, {'value': '-2.72', 'spread': '1.663', 'groupId': 'OG002'}, {'value': '-3.35', 'spread': '1.954', 'groupId': 'OG003'}, {'value': '-2.43', 'spread': '2.022', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.82', 'spread': '1.945', 'groupId': 'OG000'}, {'value': '-3.00', 'spread': '2.087', 'groupId': 'OG001'}, {'value': '-2.76', 'spread': '1.616', 'groupId': 'OG002'}, {'value': '-3.48', 'spread': '2.121', 'groupId': 'OG003'}, {'value': '-2.56', 'spread': '1.956', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.68', 'spread': '2.148', 'groupId': 'OG000'}, {'value': '-2.78', 'spread': '2.153', 'groupId': 'OG001'}, {'value': '-2.46', 'spread': '1.718', 'groupId': 'OG002'}, {'value': '-3.24', 'spread': '1.784', 'groupId': 'OG003'}, {'value': '-2.42', 'spread': '1.767', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), and 18 (Day 126)', 'description': 'The WOMAC overall score consisted of all 24 questions reported in the WOMAC questionnaire to assess: i) pain subscale, ii) PF subscale and iii) stiffness subscale. WOMAC overall score was calculated as the mean score from all 24 questions each scored on a Likert scale from 0 to 10 where higher scores represent worse outcome. Change from baseline in weekly average of WOMAC overall score to Weeks 2, 4, 6, 8, 10, 12, and 18 is reported.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in WOMAC Stiffness Scores Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.30', 'spread': '1.887', 'groupId': 'OG000'}, {'value': '-2.06', 'spread': '2.015', 'groupId': 'OG001'}, {'value': '-1.85', 'spread': '1.927', 'groupId': 'OG002'}, {'value': '-2.13', 'spread': '2.020', 'groupId': 'OG003'}, {'value': '-0.99', 'spread': '1.805', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.88', 'spread': '1.938', 'groupId': 'OG000'}, {'value': '-2.26', 'spread': '2.146', 'groupId': 'OG001'}, {'value': '-2.33', 'spread': '2.127', 'groupId': 'OG002'}, {'value': '-2.55', 'spread': '2.368', 'groupId': 'OG003'}, {'value': '-1.91', 'spread': '2.009', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '57', 'groupId': 'OG003'}, {'value': '56', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.13', 'spread': '1.837', 'groupId': 'OG000'}, {'value': '-2.79', 'spread': '2.307', 'groupId': 'OG001'}, {'value': '-2.72', 'spread': '1.871', 'groupId': 'OG002'}, {'value': '-2.97', 'spread': '2.428', 'groupId': 'OG003'}, {'value': '-2.27', 'spread': '2.314', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.99', 'spread': '2.125', 'groupId': 'OG000'}, {'value': '-2.85', 'spread': '2.260', 'groupId': 'OG001'}, {'value': '-2.85', 'spread': '2.103', 'groupId': 'OG002'}, {'value': '-3.07', 'spread': '2.104', 'groupId': 'OG003'}, {'value': '-2.39', 'spread': '2.633', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.13', 'spread': '2.060', 'groupId': 'OG000'}, {'value': '-2.99', 'spread': '2.277', 'groupId': 'OG001'}, {'value': '-2.96', 'spread': '1.977', 'groupId': 'OG002'}, {'value': '-3.29', 'spread': '2.091', 'groupId': 'OG003'}, {'value': '-2.67', 'spread': '2.329', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.29', 'spread': '2.034', 'groupId': 'OG000'}, {'value': '-3.06', 'spread': '2.380', 'groupId': 'OG001'}, {'value': '-3.06', 'spread': '2.040', 'groupId': 'OG002'}, {'value': '-3.43', 'spread': '2.407', 'groupId': 'OG003'}, {'value': '-2.85', 'spread': '2.372', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.04', 'spread': '2.192', 'groupId': 'OG000'}, {'value': '-2.76', 'spread': '2.401', 'groupId': 'OG001'}, {'value': '-2.86', 'spread': '1.988', 'groupId': 'OG002'}, {'value': '-3.17', 'spread': '1.797', 'groupId': 'OG003'}, {'value': '-2.62', 'spread': '2.152', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), and 18 (Day 126)', 'description': 'The WOMAC stiffness function subscale consists of 2 questions assessing stiffness due to OA in the target knee. Stiffness is defined as a sensation of decreased ease of movement in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC stiffness function subscale score is calculated as the mean score from the 2 questions, where higher scores represent higher stiffness. Change from baseline in WOMAC stiffness score to Weeks 2, 4, 6, 8, 10, 12, and 18 is reported.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in PGA of OA Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '60', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '57', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.35', 'spread': '0.812', 'groupId': 'OG000'}, {'value': '-0.56', 'spread': '0.917', 'groupId': 'OG001'}, {'value': '-0.67', 'spread': '0.933', 'groupId': 'OG002'}, {'value': '-0.42', 'spread': '1.059', 'groupId': 'OG003'}, {'value': '-0.37', 'spread': '0.698', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '60', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.48', 'spread': '0.738', 'groupId': 'OG000'}, {'value': '-0.68', 'spread': '1.066', 'groupId': 'OG001'}, {'value': '-0.86', 'spread': '1.043', 'groupId': 'OG002'}, {'value': '-0.86', 'spread': '1.106', 'groupId': 'OG003'}, {'value': '-0.48', 'spread': '0.792', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '45', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.57', 'spread': '0.910', 'groupId': 'OG000'}, {'value': '-0.80', 'spread': '1.026', 'groupId': 'OG001'}, {'value': '-1.02', 'spread': '1.090', 'groupId': 'OG002'}, {'value': '-1.04', 'spread': '1.098', 'groupId': 'OG003'}, {'value': '-0.51', 'spread': '0.843', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '52', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '45', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.42', 'spread': '0.723', 'groupId': 'OG000'}, {'value': '-0.76', 'spread': '0.922', 'groupId': 'OG001'}, {'value': '-1.02', 'spread': '1.010', 'groupId': 'OG002'}, {'value': '-1.06', 'spread': '1.295', 'groupId': 'OG003'}, {'value': '-0.67', 'spread': '0.826', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.39', 'spread': '0.655', 'groupId': 'OG000'}, {'value': '-0.66', 'spread': '1.022', 'groupId': 'OG001'}, {'value': '-0.83', 'spread': '1.117', 'groupId': 'OG002'}, {'value': '-1.10', 'spread': '1.294', 'groupId': 'OG003'}, {'value': '-0.56', 'spread': '0.700', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': 'The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Change from baseline in PGA of OA to Weeks 2, 4, 8, 10, and 18 is reported.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Responder Participants Measured by Osteoarthritis Research Society International (OARSI) Responder Index Using Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Definition', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '67', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '67', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '47.7', 'groupId': 'OG000'}, {'value': '62.5', 'groupId': 'OG001'}, {'value': '61.8', 'groupId': 'OG002'}, {'value': '59.7', 'groupId': 'OG003'}, {'value': '40.6', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '61', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '59.3', 'groupId': 'OG000'}, {'value': '67.7', 'groupId': 'OG001'}, {'value': '73.4', 'groupId': 'OG002'}, {'value': '65.6', 'groupId': 'OG003'}, {'value': '63.1', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '51', 'groupId': 'OG003'}, {'value': '51', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '58.9', 'groupId': 'OG000'}, {'value': '80.7', 'groupId': 'OG001'}, {'value': '80.0', 'groupId': 'OG002'}, {'value': '86.3', 'groupId': 'OG003'}, {'value': '68.6', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '59.2', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '80.0', 'groupId': 'OG002'}, {'value': '85.7', 'groupId': 'OG003'}, {'value': '67.4', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}, {'value': '47', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000'}, {'value': '78.8', 'groupId': 'OG001'}, {'value': '72.2', 'groupId': 'OG002'}, {'value': '80.5', 'groupId': 'OG003'}, {'value': '70.2', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': 'The OMERACT-OARSI responder index is calculated from the WOMAC Pain subscale, the WOMAC Physical Function Subscale and the PGA of OA. A participant is classified as a responder if: 1. \\>= 2-point absolute change from Baseline to Week X or a \\>= 50% improvement is reported in the WOMAC Pain or the PF subscales; 2. At least 2 of the following 3 conditions are true: \\>= 1-point absolute change from Baseline to Week X or \\>= 20% improvement is reported in the WOMAC Pain subscale, \\>= 1-point absolute change from Baseline to Week X or \\>= 20% improvement is reported in the WOMAC PF subscale or \\>= 1-point absolute change from Baseline to Week X is reported in the PGA of OA. Percentage of responder participants are reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Improvement of >= 2 Points in PGA of OA', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '60', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '57', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '9.7', 'groupId': 'OG000'}, {'value': '9.7', 'groupId': 'OG001'}, {'value': '16.7', 'groupId': 'OG002'}, {'value': '12.3', 'groupId': 'OG003'}, {'value': '7.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '60', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.9', 'groupId': 'OG000'}, {'value': '26.7', 'groupId': 'OG001'}, {'value': '24.6', 'groupId': 'OG002'}, {'value': '22.0', 'groupId': 'OG003'}, {'value': '6.7', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '45', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '17.0', 'groupId': 'OG000'}, {'value': '23.6', 'groupId': 'OG001'}, {'value': '25.9', 'groupId': 'OG002'}, {'value': '28.6', 'groupId': 'OG003'}, {'value': '4.4', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '10.9', 'groupId': 'OG000'}, {'value': '18.9', 'groupId': 'OG001'}, {'value': '20.4', 'groupId': 'OG002'}, {'value': '32.5', 'groupId': 'OG003'}, {'value': '7.3', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '2.3', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG001'}, {'value': '22.9', 'groupId': 'OG002'}, {'value': '25.6', 'groupId': 'OG003'}, {'value': '4.7', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': 'The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Percentage of participants with improvement of \\>= 2 points in PGA of OA at Weeks 2, 4, 8, 12, and 18 is reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Weekly Average of Daily NRS Pain Score Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '66', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '66', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.62', 'spread': '1.704', 'groupId': 'OG000'}, {'value': '-1.86', 'spread': '1.949', 'groupId': 'OG001'}, {'value': '-1.97', 'spread': '2.012', 'groupId': 'OG002'}, {'value': '-2.26', 'spread': '2.129', 'groupId': 'OG003'}, {'value': '-1.10', 'spread': '1.811', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.88', 'spread': '1.653', 'groupId': 'OG000'}, {'value': '-2.50', 'spread': '2.163', 'groupId': 'OG001'}, {'value': '-2.68', 'spread': '2.177', 'groupId': 'OG002'}, {'value': '-2.65', 'spread': '2.333', 'groupId': 'OG003'}, {'value': '-1.66', 'spread': '1.854', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '61', 'groupId': 'OG002'}, {'value': '57', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.17', 'spread': '1.687', 'groupId': 'OG000'}, {'value': '-2.83', 'spread': '2.248', 'groupId': 'OG001'}, {'value': '-3.00', 'spread': '2.192', 'groupId': 'OG002'}, {'value': '-3.35', 'spread': '2.498', 'groupId': 'OG003'}, {'value': '-1.97', 'spread': '2.020', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '61', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.27', 'spread': '1.736', 'groupId': 'OG000'}, {'value': '-2.91', 'spread': '2.084', 'groupId': 'OG001'}, {'value': '-3.09', 'spread': '2.205', 'groupId': 'OG002'}, {'value': '-3.45', 'spread': '2.365', 'groupId': 'OG003'}, {'value': '-2.18', 'spread': '2.274', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '51', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.38', 'spread': '2.001', 'groupId': 'OG000'}, {'value': '-3.18', 'spread': '1.930', 'groupId': 'OG001'}, {'value': '-3.24', 'spread': '2.294', 'groupId': 'OG002'}, {'value': '-3.57', 'spread': '2.274', 'groupId': 'OG003'}, {'value': '-2.28', 'spread': '2.047', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '38', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.08', 'spread': '2.120', 'groupId': 'OG000'}, {'value': '-3.18', 'spread': '2.237', 'groupId': 'OG001'}, {'value': '-2.90', 'spread': '2.157', 'groupId': 'OG002'}, {'value': '-3.63', 'spread': '2.383', 'groupId': 'OG003'}, {'value': '-2.45', 'spread': '1.969', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -7 to Day -1, inclusive), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': 'The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This will be recorded on a daily basis at approximately the same time every morning via ePRO diary. Change from baseline in weekly average of daily NRS to Weeks 2, 4, 6, 8, 10, and 18 is reported.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With >= 30% and >= 50% Reductions in Weekly Average of Daily NRS Pain Score Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '66', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': '>=30%: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '66', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '34.8', 'groupId': 'OG000'}, {'value': '34.4', 'groupId': 'OG001'}, {'value': '41.5', 'groupId': 'OG002'}, {'value': '43.9', 'groupId': 'OG003'}, {'value': '21.5', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '47.5', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG001'}, {'value': '64.1', 'groupId': 'OG002'}, {'value': '53.8', 'groupId': 'OG003'}, {'value': '29.7', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '61', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '56.4', 'groupId': 'OG000'}, {'value': '67.8', 'groupId': 'OG001'}, {'value': '67.2', 'groupId': 'OG002'}, {'value': '61.5', 'groupId': 'OG003'}, {'value': '42.3', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '50', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '58.0', 'groupId': 'OG000'}, {'value': '76.4', 'groupId': 'OG001'}, {'value': '65.5', 'groupId': 'OG002'}, {'value': '72.7', 'groupId': 'OG003'}, {'value': '47.8', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '38', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}, {'value': '72.9', 'groupId': 'OG001'}, {'value': '67.3', 'groupId': 'OG002'}, {'value': '65.8', 'groupId': 'OG003'}, {'value': '54.5', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '66', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '15.2', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '29.2', 'groupId': 'OG002'}, {'value': '30.3', 'groupId': 'OG003'}, {'value': '13.8', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '24.6', 'groupId': 'OG000'}, {'value': '32.8', 'groupId': 'OG001'}, {'value': '40.6', 'groupId': 'OG002'}, {'value': '36.9', 'groupId': 'OG003'}, {'value': '15.6', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '61', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '32.7', 'groupId': 'OG000'}, {'value': '45.8', 'groupId': 'OG001'}, {'value': '54.1', 'groupId': 'OG002'}, {'value': '57.7', 'groupId': 'OG003'}, {'value': '26.9', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '50', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '44.0', 'groupId': 'OG000'}, {'value': '54.5', 'groupId': 'OG001'}, {'value': '49.1', 'groupId': 'OG002'}, {'value': '54.5', 'groupId': 'OG003'}, {'value': '26.1', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '38', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '26.2', 'groupId': 'OG000'}, {'value': '54.2', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '52.6', 'groupId': 'OG003'}, {'value': '29.5', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Day -7 to Day -1, inclusive), Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': 'The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This will be recorded on a daily basis at approximately the same time every morning via ePRO diary. Percentage of participants with \\>= 30% and \\>= 50% reductions in weekly average of daily NRS pain score are reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With >= 30% and >= 50% Reductions in WOMAC Pain Subscale Score Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': '>=30%: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '30.2', 'groupId': 'OG000'}, {'value': '39.7', 'groupId': 'OG001'}, {'value': '36.5', 'groupId': 'OG002'}, {'value': '50.8', 'groupId': 'OG003'}, {'value': '24.1', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '40.4', 'groupId': 'OG000'}, {'value': '54.1', 'groupId': 'OG001'}, {'value': '61.7', 'groupId': 'OG002'}, {'value': '61.0', 'groupId': 'OG003'}, {'value': '47.5', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '55.6', 'groupId': 'OG000'}, {'value': '64.3', 'groupId': 'OG001'}, {'value': '64.9', 'groupId': 'OG002'}, {'value': '71.4', 'groupId': 'OG003'}, {'value': '56.5', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '59.6', 'groupId': 'OG000'}, {'value': '68.5', 'groupId': 'OG001'}, {'value': '67.3', 'groupId': 'OG002'}, {'value': '75.0', 'groupId': 'OG003'}, {'value': '66.7', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '51.1', 'groupId': 'OG000'}, {'value': '70.6', 'groupId': 'OG001'}, {'value': '62.7', 'groupId': 'OG002'}, {'value': '76.9', 'groupId': 'OG003'}, {'value': '69.8', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '23.8', 'groupId': 'OG001'}, {'value': '17.5', 'groupId': 'OG002'}, {'value': '33.8', 'groupId': 'OG003'}, {'value': '10.3', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '24.6', 'groupId': 'OG000'}, {'value': '31.1', 'groupId': 'OG001'}, {'value': '40.0', 'groupId': 'OG002'}, {'value': '55.9', 'groupId': 'OG003'}, {'value': '26.2', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '35.2', 'groupId': 'OG000'}, {'value': '46.4', 'groupId': 'OG001'}, {'value': '49.1', 'groupId': 'OG002'}, {'value': '57.1', 'groupId': 'OG003'}, {'value': '34.8', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '31.9', 'groupId': 'OG000'}, {'value': '51.9', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '62.5', 'groupId': 'OG003'}, {'value': '42.9', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '51.0', 'groupId': 'OG001'}, {'value': '43.1', 'groupId': 'OG002'}, {'value': '59.0', 'groupId': 'OG003'}, {'value': '41.9', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to OA in the target knee. Each question was scored on an NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Percentage of participants with \\>= 30% and \\>= 50% reductions in WOMAC pain subscale score over time are reported.", 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With >= 30% and >= 50% Reductions in WOMAC Physical Function Subscale Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': '>=30%: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '30.2', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '39.7', 'groupId': 'OG002'}, {'value': '47.7', 'groupId': 'OG003'}, {'value': '22.4', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '47.4', 'groupId': 'OG000'}, {'value': '52.5', 'groupId': 'OG001'}, {'value': '61.7', 'groupId': 'OG002'}, {'value': '59.3', 'groupId': 'OG003'}, {'value': '37.7', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '64.3', 'groupId': 'OG001'}, {'value': '63.2', 'groupId': 'OG002'}, {'value': '69.4', 'groupId': 'OG003'}, {'value': '47.8', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42.6', 'groupId': 'OG000'}, {'value': '72.2', 'groupId': 'OG001'}, {'value': '67.3', 'groupId': 'OG002'}, {'value': '72.5', 'groupId': 'OG003'}, {'value': '54.8', 'groupId': 'OG004'}]}]}, {'title': '>=30%: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42.2', 'groupId': 'OG000'}, {'value': '72.5', 'groupId': 'OG001'}, {'value': '64.7', 'groupId': 'OG002'}, {'value': '74.4', 'groupId': 'OG003'}, {'value': '60.5', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '22.2', 'groupId': 'OG001'}, {'value': '23.8', 'groupId': 'OG002'}, {'value': '33.8', 'groupId': 'OG003'}, {'value': '12.1', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '28.1', 'groupId': 'OG000'}, {'value': '31.1', 'groupId': 'OG001'}, {'value': '41.7', 'groupId': 'OG002'}, {'value': '54.2', 'groupId': 'OG003'}, {'value': '19.7', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '46', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '51.8', 'groupId': 'OG001'}, {'value': '47.4', 'groupId': 'OG002'}, {'value': '57.1', 'groupId': 'OG003'}, {'value': '26.1', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '34.0', 'groupId': 'OG000'}, {'value': '46.3', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '62.5', 'groupId': 'OG003'}, {'value': '35.7', 'groupId': 'OG004'}]}]}, {'title': '>=50%: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}, {'value': '45.1', 'groupId': 'OG001'}, {'value': '39.2', 'groupId': 'OG002'}, {'value': '59.0', 'groupId': 'OG003'}, {'value': '34.9', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': "The WOMAC PF subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Percentage of participants with \\>= 30% and \\>= 50% reductions in WOMAC physical function subscale over time are reported.", 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Serum Concentration of MEDI7352', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '67', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '326.863', 'spread': '98.989', 'groupId': 'OG000'}, {'value': '681.322', 'spread': '159.914', 'groupId': 'OG001'}, {'value': '2149.062', 'spread': '109.2763', 'groupId': 'OG002'}, {'value': '3582.265', 'spread': '364.200', 'groupId': 'OG003'}]}]}, {'title': 'Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '67', 'groupId': 'OG002'}, {'value': '67', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '50.337', 'spread': '538.604', 'groupId': 'OG000'}, {'value': '144.242', 'spread': '475.607', 'groupId': 'OG001'}, {'value': '379.882', 'spread': '488.933', 'groupId': 'OG002'}, {'value': '650.864', 'spread': '624.642', 'groupId': 'OG003'}]}]}, {'title': 'Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '62', 'groupId': 'OG002'}, {'value': '56', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '11.025', 'spread': '853.538', 'groupId': 'OG000'}, {'value': '28.332', 'spread': '2745.856', 'groupId': 'OG001'}, {'value': '43.644', 'spread': '6705.491', 'groupId': 'OG002'}, {'value': '222.665', 'spread': '3963.855', 'groupId': 'OG003'}]}]}, {'title': 'Day 42', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '59', 'groupId': 'OG002'}, {'value': '50', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '5.895', 'spread': '846.517', 'groupId': 'OG000'}, {'value': '12.375', 'spread': '2578.767', 'groupId': 'OG001'}, {'value': '30.005', 'spread': '11978.840', 'groupId': 'OG002'}, {'value': '116.951', 'spread': '14993.947', 'groupId': 'OG003'}]}]}, {'title': 'Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}, {'value': '51', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '6.625', 'spread': '2133.678', 'groupId': 'OG001'}, {'value': '20.546', 'spread': '13626.951', 'groupId': 'OG002'}, {'value': '85.779', 'spread': '15987.305', 'groupId': 'OG003'}]}]}, {'title': 'Day 70', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '17.124', 'spread': '15147.088', 'groupId': 'OG002'}, {'value': '57.042', 'spread': '18183.372', 'groupId': 'OG003'}]}]}, {'title': 'Day 74', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '10.943', 'spread': '1833.135', 'groupId': 'OG000'}, {'value': '22.074', 'spread': '4305.129', 'groupId': 'OG001'}, {'value': '116.544', 'spread': '25316.322', 'groupId': 'OG002'}, {'value': '551.099', 'spread': '18558.506', 'groupId': 'OG003'}]}]}, {'title': 'Day 77', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '44', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '5.011', 'spread': '1322.708', 'groupId': 'OG000'}, {'value': '9.356', 'spread': '3099.752', 'groupId': 'OG001'}, {'value': '47.108', 'spread': '39692.068', 'groupId': 'OG002'}, {'value': '271.511', 'spread': '36387.885', 'groupId': 'OG003'}]}]}, {'title': 'Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '10.482', 'spread': '6086.596', 'groupId': 'OG002'}, {'value': '43.062', 'spread': '13640.856', 'groupId': 'OG003'}]}]}, {'title': 'Day 126', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Day 224', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Baseline (Day 1), Day 7; pre-dose on Days 14, 28, 42, 56, and 70; and on Days 74, 77, 84, 126, and 224', 'description': 'Serum concentration of MEDI7352 is reported.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) analysis set included participants who received at least one dose of double-blind study treatment per the protocol for whom any post-baseline PK data are available and who did not violate or deviate from the protocol in ways that would significantly affect the PK analyses. Number of participants analyzed (N) denotes those participants who were analyzed for this outcome measure. Number analyzed (n) denotes those participants who had adequate serum samples.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Positive Anti-Drug Antibodies (ADA) to MEDI7352', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '67', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Treatment-induced ADA positive', 'categories': [{'measurements': [{'value': '52', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}]}, {'title': 'Treatment-boosted ADA positive', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Persistent positive ADA', 'categories': [{'measurements': [{'value': '43', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}]}, {'title': 'Transiently positive ADA', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day 1), Day 7; pre-dose on Days 14, 28, 42, 56, and 70; and on Days 74, 77, 84, 126, and 224', 'description': 'Number of participants with ADA to MEDI7352 are reported. Treatment-induced ADA positive is defined as ADA negative at baseline and positive at least 1 post-baseline ADA assessment. Treatment-boosted ADA positive is defined as ADA positive at baseline, and the baseline titre is boosted by greater than the variability of the assay (commonly 4-fold) at \\>= 1 post-baseline timepoint. Persistent positive is defined as ADA negative at baseline and having at least 2 post-baseline ADA positive assessments (with \\>= 16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as ADA negative at baseline and at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'ADA evaluable participants included all participants in the safety analysis set who have a non-missing baseline and at least one non-missing post-baseline ADA results. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who had adequate ADA sample.'}, {'type': 'SECONDARY', 'title': 'ADA Titre in Participants Who Were ADA Positive at Baseline and/or Post-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '54', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '960.0', 'groupId': 'OG000', 'lowerLimit': '30', 'upperLimit': '122880'}, {'value': '960.0', 'groupId': 'OG001', 'lowerLimit': '30', 'upperLimit': '245760'}, {'value': '960.0', 'groupId': 'OG002', 'lowerLimit': '30', 'upperLimit': '15360'}, {'value': '720.0', 'groupId': 'OG003', 'lowerLimit': '30', 'upperLimit': '122880'}, {'value': '240.0', 'groupId': 'OG004', 'lowerLimit': '30', 'upperLimit': '3840'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline (Day 1), Day 7; pre-dose on Days 14, 28, 42, 56, and 70; and on Days 74, 77, 84, 126, and 224', 'description': 'The ADA titre in participants who were ADA positive at baseline and/or post-baseline is reported.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'ADA evaluable participants included all participants in safety analysis set who have non-missing baseline and at least 1 non-missing post-baseline ADA results. Number of participants analyzed (N): number of participants who were ADA positive at baseline and/or post-baseline. Number analyzed (n): participants who had adequate ADA sample.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Any TEAEs', 'categories': [{'measurements': [{'value': '51', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}, {'value': '51', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}]}]}, {'title': 'Any TESAEs', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Findings in Physical Examination Reported as TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with clinically significant findings in physical examination reported as TEAE are reported. A physical examination included assessments of general appearance, skin, head and neck, examination of the oral cavity for any lesions, lymph nodes, thyroid, abdomen (bowel sounds, liver, and spleen palpation), back (including costovertebral angle tenderness), musculoskeletal/extremities, cardiovascular, and respiratory systems.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormal Findings in Neurological Examination', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 0', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -45 to Day -1), Weeks 0 (Day 1), 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), 18 (Day 126), 28 (Day 168), 32 (Day 224), and 36 (Day 252)', 'description': 'Number of participants with clinically significant abnormal findings in neurological examination is reported. The neurological examination included assessment of mental status, cranial nerves, motor examination (muscle strength and tone), upper and lower extremity deep tendon reflexes, plantar responses, sensory system examination, coordination, and gait.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}, {'type': 'SECONDARY', 'title': 'Total Neuropathy Score-Nurse (TNSn) Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '59', 'groupId': 'OG002'}, {'value': '56', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '2.40', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '1.94', 'groupId': 'OG001'}, {'value': '1.0', 'spread': '1.56', 'groupId': 'OG002'}, {'value': '1.2', 'spread': '1.69', 'groupId': 'OG003'}, {'value': '1.5', 'spread': '2.02', 'groupId': 'OG004'}]}]}, {'title': 'Week 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '1.92', 'groupId': 'OG000'}, {'value': '1.7', 'spread': '2.26', 'groupId': 'OG001'}, {'value': '1.4', 'spread': '2.03', 'groupId': 'OG002'}, {'value': '1.5', 'spread': '2.29', 'groupId': 'OG003'}, {'value': '1.8', 'spread': '2.26', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '65', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '67', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '1.84', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '2.42', 'groupId': 'OG001'}, {'value': '1.2', 'spread': '1.97', 'groupId': 'OG002'}, {'value': '1.0', 'spread': '1.70', 'groupId': 'OG003'}, {'value': '1.5', 'spread': '2.18', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '64', 'groupId': 'OG002'}, {'value': '64', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.66', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '1.98', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '1.54', 'groupId': 'OG002'}, {'value': '0.9', 'spread': '1.61', 'groupId': 'OG003'}, {'value': '1.4', 'spread': '2.16', 'groupId': 'OG004'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '62', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}, {'value': '61', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.55', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '2.23', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '1.73', 'groupId': 'OG002'}, {'value': '0.9', 'spread': '1.48', 'groupId': 'OG003'}, {'value': '1.5', 'spread': '2.51', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '62', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.65', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '1.86', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '0.91', 'groupId': 'OG002'}, {'value': '0.8', 'spread': '1.62', 'groupId': 'OG003'}, {'value': '1.2', 'spread': '1.84', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '51', 'groupId': 'OG003'}, {'value': '50', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '1.85', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '2.06', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '1.53', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '1.20', 'groupId': 'OG003'}, {'value': '1.1', 'spread': '2.10', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '59', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '49', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.35', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '1.88', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '1.37', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '1.23', 'groupId': 'OG003'}, {'value': '1.1', 'spread': '2.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '2.25', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '2.69', 'groupId': 'OG001'}, {'value': '2.5', 'spread': '2.83', 'groupId': 'OG002'}, {'value': '0.8', 'spread': '0.92', 'groupId': 'OG003'}, {'value': '2.9', 'spread': '2.67', 'groupId': 'OG004'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '43', 'groupId': 'OG003'}, {'value': '48', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '1.98', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '1.50', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '0.88', 'groupId': 'OG002'}, {'value': '0.9', 'spread': '1.64', 'groupId': 'OG003'}, {'value': '1.0', 'spread': '1.98', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -45 to Day -1), Weeks 0 (Day 1), 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), 28 (Day 196), and 32 (Day 224)', 'description': 'The TNSn, is a semiquantitative clinical assessment of peripheral nervous system function. The TNSn assessment is collected as scores of motor symptom, autonomic symptom, pin sensibility, sensory symptom, and vibration sensibility score. Each neuropathy item is scored on a 0 to 4 scale with total score ranging from 0 to 20. Higher total scores correlate with more severe neuropathy.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Weight (kg) to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}, {'value': '66', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.25', 'spread': '2.048', 'groupId': 'OG000'}, {'value': '0.10', 'spread': '2.343', 'groupId': 'OG001'}, {'value': '0.34', 'spread': '1.932', 'groupId': 'OG002'}, {'value': '-0.03', 'spread': '1.864', 'groupId': 'OG003'}, {'value': '-0.34', 'spread': '2.004', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -45 to -1) and Week 12', 'description': 'Change from baseline in weight (kg) to Week 12 is reported.', 'unitOfMeasure': 'kg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants evaluated at Week 12'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Abnormal Vital Signs Reported as TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Bradycardia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Tachycardia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Tachycardia paroxysmal', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Hypertension', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Hypertensive crisis', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Orthostatic hypotension', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Pyrexia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormalfinding in the vital sign parameters (body temperature, supine and standing blood pressure, pulse rate, and respiratory rate).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Survey of Autonomic Symptoms (SAS) Total Impact Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}, {'value': '38', 'groupId': 'OG003'}, {'value': '44', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.5', 'spread': '4.78', 'groupId': 'OG000'}, {'value': '-1.1', 'spread': '4.63', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '4.13', 'groupId': 'OG002'}, {'value': '-1.6', 'spread': '4.62', 'groupId': 'OG003'}, {'value': '-0.8', 'spread': '3.50', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1; Week 0) and Day 252 (Week 36)', 'description': 'The SAS is an instrument that measures autonomic symptoms used for assessing autonomic neuropathies in clinical trials. The SAS scale evaluates the presence of symptoms and the degree of severity. The SAS consists of 11 questions in women and 12 questions in men. Each question has a Yes or No answer to symptoms occurring 6 months prior to investigational product (IP) administration. Questions answered with "Yes" are further rated by asking the participant how much each symptom is bothering him or her. Each answer is scored on a scale from 1 to 5 where 1 = not at all and 5 = a lot, and a total symptom impact score is determined. The SAS total impact score is the total of the scores from each question (11 for women and 12 for men). The minimum score is 0 and the maximum is 55 for women and 60 for men. A higher score indicates worse autonomic dysfunction.', 'unitOfMeasure': 'Unit on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who had adequate SAS impact score.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'Week 0', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '66', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}, {'value': '64', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '60', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '49', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}, {'value': '50', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '67', 'groupId': 'OG002'}, {'value': '65', 'groupId': 'OG003'}, {'value': '65', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '49', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Weeks 0 (Day 1), 2 (Day 14), 4 (Day 28), 8 (Day 56), 10 (Day 70), 12 (Day 84), 28 (Day 168), and 32 (Day 224)', 'description': 'Number of participants with clinically significant abnormal ECGs are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'COVID-19', 'categories': [{'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}]}, {'title': 'Anaemia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Leukopenia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Lymphopenia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Neutropenia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Hypercholesterolaemia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Hyperkalaemia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Hypertriglyceridaemia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Hypokalaemia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Hyponatraemia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Type 2 diabetes mellitus', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Vitamin D deficiency', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Glycosuria', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Leukocyturia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Proteinuria', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Activated partial thromboplastin time prolonged', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Alanine aminotransferase increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Aspartate aminotransferase increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Blood creatine phosphokinase increased', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Blood folate decreased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Blood glucose increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Blood uric acid increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'C-reactive protein increased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Coagulation factor increased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Gamma-glutamyltransferase increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Glycosylated haemoglobin increased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in C-reactive Protein Level to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '50', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}, {'value': '43', 'groupId': 'OG003'}, {'value': '45', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.55', 'spread': '1.975', 'groupId': 'OG000'}, {'value': '-3.34', 'spread': '2.004', 'groupId': 'OG001'}, {'value': '-3.30', 'spread': '2.422', 'groupId': 'OG002'}, {'value': '-3.68', 'spread': '2.313', 'groupId': 'OG003'}, {'value': '-2.38', 'spread': '1.971', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -7 to -1, inclusive) and Week 12', 'description': 'Change from baseline in C-reactive protein level to Week 12 is reported.', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated at Week 12.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Injection Site Reactions', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with injection site reactions are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Abnormal X-ray and/or Magnetic Resonance Imaging (MRI) of Large Joints', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '69', 'groupId': 'OG002'}, {'value': '68', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'OG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'classes': [{'title': 'X-ray', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'MRI', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline (Day -45 to -1) and Week 32', 'description': 'Number of participants with abnormal X-ray and/or MRI of large joints is reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'FG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'FG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'FG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'FG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '70'}, {'groupId': 'FG001', 'numSubjects': '68'}, {'groupId': 'FG002', 'numSubjects': '69'}, {'groupId': 'FG003', 'numSubjects': '68'}, {'groupId': 'FG004', 'numSubjects': '70'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '70'}, {'groupId': 'FG001', 'numSubjects': '68'}, {'groupId': 'FG002', 'numSubjects': '69'}, {'groupId': 'FG003', 'numSubjects': '68'}, {'groupId': 'FG004', 'numSubjects': '69'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '59'}, {'groupId': 'FG001', 'numSubjects': '64'}, {'groupId': 'FG002', 'numSubjects': '65'}, {'groupId': 'FG003', 'numSubjects': '57'}, {'groupId': 'FG004', 'numSubjects': '61'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '11'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '11'}, {'groupId': 'FG004', 'numSubjects': '9'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '6'}]}]}], 'recruitmentDetails': 'The study was conducted at 50 sites in 6 countries (the United Kingdom, Denmark, Estonia, Germany, Poland, and Spain).', 'preAssignmentDetails': 'A total of 345 participants were randomized, of which 344 participants received at least one dose of study drug.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'BG000'}, {'value': '68', 'groupId': 'BG001'}, {'value': '69', 'groupId': 'BG002'}, {'value': '68', 'groupId': 'BG003'}, {'value': '70', 'groupId': 'BG004'}, {'value': '345', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'MEDl7352 Dose Level 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose Level 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.'}, {'id': 'BG001', 'title': 'MEDl7352 Dose Level 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 2 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'BG002', 'title': 'MEDl7352 Dose Level 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 3 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'BG003', 'title': 'MEDl7352 Dose Level 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose Level 4 injection Q2W during a 12-week parallel-group treatment period.'}, {'id': 'BG004', 'title': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '65.8', 'spread': '7.90', 'groupId': 'BG000'}, {'value': '63.3', 'spread': '7.73', 'groupId': 'BG001'}, {'value': '63.8', 'spread': '6.91', 'groupId': 'BG002'}, {'value': '63.3', 'spread': '7.52', 'groupId': 'BG003'}, {'value': '62.5', 'spread': '8.03', 'groupId': 'BG004'}, {'value': '63.7', 'spread': '7.67', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '51', 'groupId': 'BG001'}, {'value': '48', 'groupId': 'BG002'}, {'value': '46', 'groupId': 'BG003'}, {'value': '42', 'groupId': 'BG004'}, {'value': '230', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '27', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '21', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}, {'value': '28', 'groupId': 'BG004'}, {'value': '115', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '69', 'groupId': 'BG000'}, {'value': '67', 'groupId': 'BG001'}, {'value': '67', 'groupId': 'BG002'}, {'value': '67', 'groupId': 'BG003'}, {'value': '70', 'groupId': 'BG004'}, {'value': '340', 'groupId': 'BG005'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': 'White', 'measurements': [{'value': '69', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '67', 'groupId': 'BG002'}, {'value': '65', 'groupId': 'BG003'}, {'value': '67', 'groupId': 'BG004'}, {'value': '334', 'groupId': 'BG005'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Full analysis set included all randomized participants analyzed according to the Intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-06-28', 'size': 4617473, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-11-25T07:33', 'hasProtocol': True}, {'date': '2023-09-13', 'size': 2842220, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-11-25T07:33', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'All participants will be centrally assigned to randomised IP using an Interactive Response Technology/Randomisation and Trial Supply Management (IRT/RTSM) system. Before the study is initiated, telephone number and call-in directions for IRT and/or log in information and directions for RTSM will be provided to each site.\n\nThe IRT/RTSM will provide investigator(s) or appropriate study personnel with kit identification number to be allocated to participant at IP dosing visit.\n\nDetails for this will be described in IRT/RTSM user manual that will be provided to each centre.\n\nAll participants, investigators, and study personnel involved in conduct of the study will be blinded to treatment assignment. The unblinded study personnel (eg, site pharmacist) will not participate in study procedures or data analysis prior to unblinding of study data to all study-related personnel. Unblinded AstraZeneca personnel who are not otherwise involved in study will prepare data for review and interim analyses.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This is a Phase IIb, multinational, multicentre, randomised, double-blind, placebo-controlled, dose-response study of MEDI7352 in participants 18 to 80 years of age (inclusive) with moderate-to-severe chronic pain of the knee. The study consists of a screening period of up to 45 days, a 12-week treatment period, and a 24-week follow-up (FU) period.\n\nDaily pain scores (as measured on an 11-point numerical rating scale \\[NRS\\]) recorded at the first screening visit and from Day -7 to Day -1 will be used be used to determine eligibility.\n\nParticipants will be randomised to one of 4 doses of MEDI7352 or placebo. Each participant will receive 6 doses of MEDI7352 or placebo during the treatment period.\n\nAfter the end-of-treatment (EOT) visit at Week 12, participants will enter the FU period, which comprises 3 clinic visits (Weeks 18, 32, and 36) and 4 FU phone calls (Weeks 15, 21, 24, and 28). All participants who receive investigational product (IP) are expected to complete the FU period.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 345}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-12-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2023-08-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-07', 'studyFirstSubmitDate': '2020-11-23', 'resultsFirstSubmitDate': '2024-08-15', 'studyFirstSubmitQcDate': '2020-12-14', 'lastUpdatePostDateStruct': {'date': '2025-02-10', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-02-07', 'studyFirstPostDateStruct': {'date': '2020-12-19', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-02-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-08-16', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Weekly Average of Daily Numerical Rating Scale (NRS) Pain Score to Week 12', 'timeFrame': 'Baseline (Day -7 to Day -1, inclusive) through Week 12', 'description': 'Change from baseline in weekly average of daily NRS pain score to Week 12 is reported. The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This was recorded on a daily basis at approximately the same time every morning via electronic patient recorded outcome (ePRO) diary. A two-step multiple imputation procedure was used to address missing post-baseline scores.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscale to Week 12', 'timeFrame': 'Week 0 (Day 1; baseline) through Week 12', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to osteoarthritis (OA) in the target knee. Each question was scored on a NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Change from baseline in WOMAC pain subscale to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores."}, {'measure': 'Change From Baseline in WOMAC Physical Function Subscale to Week 12', 'timeFrame': 'Week 0 (Day 1; baseline) through Week 12', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC physical function (PF) subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Change from baseline in WOMAC physical function to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores."}, {'measure': "Change From Baseline in Patient's Global Assessment (PGA) of OA to Week 12", 'timeFrame': 'Week 0 (Day 1; baseline) through Week 12', 'description': 'The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Change from baseline in PGA of OA to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.'}, {'measure': 'Change From Baseline in WOMAC Pain Subscale Over Time', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to OA in the target knee. Each question was scored on an NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Change from baseline in WOMAC pain subscale to Weeks 2, 4,6, 8, 10, and 18 is reported."}, {'measure': 'Change From Baseline in WOMAC PF Subscale Over Time', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC PF subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Change from baseline in WOMAC physical function to Weeks 2, 4, 6, 8, 10, and 18 is reported."}, {'measure': 'Change From Baseline in WOMAC Overall Score Over Time', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), and 18 (Day 126)', 'description': 'The WOMAC overall score consisted of all 24 questions reported in the WOMAC questionnaire to assess: i) pain subscale, ii) PF subscale and iii) stiffness subscale. WOMAC overall score was calculated as the mean score from all 24 questions each scored on a Likert scale from 0 to 10 where higher scores represent worse outcome. Change from baseline in weekly average of WOMAC overall score to Weeks 2, 4, 6, 8, 10, 12, and 18 is reported.'}, {'measure': 'Change From Baseline in WOMAC Stiffness Scores Over Time', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), and 18 (Day 126)', 'description': 'The WOMAC stiffness function subscale consists of 2 questions assessing stiffness due to OA in the target knee. Stiffness is defined as a sensation of decreased ease of movement in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC stiffness function subscale score is calculated as the mean score from the 2 questions, where higher scores represent higher stiffness. Change from baseline in WOMAC stiffness score to Weeks 2, 4, 6, 8, 10, 12, and 18 is reported.'}, {'measure': 'Change From Baseline in PGA of OA Over Time', 'timeFrame': 'Baseline, Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': 'The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Change from baseline in PGA of OA to Weeks 2, 4, 8, 10, and 18 is reported.'}, {'measure': 'Percentage of Responder Participants Measured by Osteoarthritis Research Society International (OARSI) Responder Index Using Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Definition', 'timeFrame': 'Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': 'The OMERACT-OARSI responder index is calculated from the WOMAC Pain subscale, the WOMAC Physical Function Subscale and the PGA of OA. A participant is classified as a responder if: 1. \\>= 2-point absolute change from Baseline to Week X or a \\>= 50% improvement is reported in the WOMAC Pain or the PF subscales; 2. At least 2 of the following 3 conditions are true: \\>= 1-point absolute change from Baseline to Week X or \\>= 20% improvement is reported in the WOMAC Pain subscale, \\>= 1-point absolute change from Baseline to Week X or \\>= 20% improvement is reported in the WOMAC PF subscale or \\>= 1-point absolute change from Baseline to Week X is reported in the PGA of OA. Percentage of responder participants are reported.'}, {'measure': 'Percentage of Participants With Improvement of >= 2 Points in PGA of OA', 'timeFrame': 'Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': 'The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Percentage of participants with improvement of \\>= 2 points in PGA of OA at Weeks 2, 4, 8, 12, and 18 is reported.'}, {'measure': 'Change From Baseline in Weekly Average of Daily NRS Pain Score Over Time', 'timeFrame': 'Baseline (Day -7 to Day -1, inclusive), Weeks 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), and 18 (Day 126)', 'description': 'The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This will be recorded on a daily basis at approximately the same time every morning via ePRO diary. Change from baseline in weekly average of daily NRS to Weeks 2, 4, 6, 8, 10, and 18 is reported.'}, {'measure': 'Percentage of Participants With >= 30% and >= 50% Reductions in Weekly Average of Daily NRS Pain Score Over Time', 'timeFrame': 'Baseline (Day -7 to Day -1, inclusive), Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': 'The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This will be recorded on a daily basis at approximately the same time every morning via ePRO diary. Percentage of participants with \\>= 30% and \\>= 50% reductions in weekly average of daily NRS pain score are reported.'}, {'measure': 'Percentage of Participants With >= 30% and >= 50% Reductions in WOMAC Pain Subscale Score Over Time', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': "The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to OA in the target knee. Each question was scored on an NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Percentage of participants with \\>= 30% and \\>= 50% reductions in WOMAC pain subscale score over time are reported."}, {'measure': 'Percentage of Participants With >= 30% and >= 50% Reductions in WOMAC Physical Function Subscale Over Time', 'timeFrame': 'Baseline (Week 0; Day 1), Weeks 2 (Day 14), 4 (Day 28), 8 (Day 56), 12 (Day 84), and 18 (Day 126)', 'description': "The WOMAC PF subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Percentage of participants with \\>= 30% and \\>= 50% reductions in WOMAC physical function subscale over time are reported."}, {'measure': 'Serum Concentration of MEDI7352', 'timeFrame': 'Baseline (Day 1), Day 7; pre-dose on Days 14, 28, 42, 56, and 70; and on Days 74, 77, 84, 126, and 224', 'description': 'Serum concentration of MEDI7352 is reported.'}, {'measure': 'Number of Participants With Positive Anti-Drug Antibodies (ADA) to MEDI7352', 'timeFrame': 'Baseline (Day 1), Day 7; pre-dose on Days 14, 28, 42, 56, and 70; and on Days 74, 77, 84, 126, and 224', 'description': 'Number of participants with ADA to MEDI7352 are reported. Treatment-induced ADA positive is defined as ADA negative at baseline and positive at least 1 post-baseline ADA assessment. Treatment-boosted ADA positive is defined as ADA positive at baseline, and the baseline titre is boosted by greater than the variability of the assay (commonly 4-fold) at \\>= 1 post-baseline timepoint. Persistent positive is defined as ADA negative at baseline and having at least 2 post-baseline ADA positive assessments (with \\>= 16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as ADA negative at baseline and at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.'}, {'measure': 'ADA Titre in Participants Who Were ADA Positive at Baseline and/or Post-baseline', 'timeFrame': 'Baseline (Day 1), Day 7; pre-dose on Days 14, 28, 42, 56, and 70; and on Days 74, 77, 84, 126, and 224', 'description': 'The ADA titre in participants who were ADA positive at baseline and/or post-baseline is reported.'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.'}, {'measure': 'Number of Participants With Clinically Significant Findings in Physical Examination Reported as TEAEs', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with clinically significant findings in physical examination reported as TEAE are reported. A physical examination included assessments of general appearance, skin, head and neck, examination of the oral cavity for any lesions, lymph nodes, thyroid, abdomen (bowel sounds, liver, and spleen palpation), back (including costovertebral angle tenderness), musculoskeletal/extremities, cardiovascular, and respiratory systems.'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Findings in Neurological Examination', 'timeFrame': 'Baseline (Day -45 to Day -1), Weeks 0 (Day 1), 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), 18 (Day 126), 28 (Day 168), 32 (Day 224), and 36 (Day 252)', 'description': 'Number of participants with clinically significant abnormal findings in neurological examination is reported. The neurological examination included assessment of mental status, cranial nerves, motor examination (muscle strength and tone), upper and lower extremity deep tendon reflexes, plantar responses, sensory system examination, coordination, and gait.'}, {'measure': 'Total Neuropathy Score-Nurse (TNSn) Over Time', 'timeFrame': 'Baseline (Day -45 to Day -1), Weeks 0 (Day 1), 2 (Day 14), 4 (Day 28), 6 (Day 42), 8 (Day 56), 10 (Day 70), 12 (Day 84), 28 (Day 196), and 32 (Day 224)', 'description': 'The TNSn, is a semiquantitative clinical assessment of peripheral nervous system function. The TNSn assessment is collected as scores of motor symptom, autonomic symptom, pin sensibility, sensory symptom, and vibration sensibility score. Each neuropathy item is scored on a 0 to 4 scale with total score ranging from 0 to 20. Higher total scores correlate with more severe neuropathy.'}, {'measure': 'Change From Baseline in Weight (kg) to Week 12', 'timeFrame': 'Baseline (Day -45 to -1) and Week 12', 'description': 'Change from baseline in weight (kg) to Week 12 is reported.'}, {'measure': 'Number of Participants With Abnormal Vital Signs Reported as TEAEs', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormalfinding in the vital sign parameters (body temperature, supine and standing blood pressure, pulse rate, and respiratory rate).'}, {'measure': 'Change From Baseline in Survey of Autonomic Symptoms (SAS) Total Impact Score', 'timeFrame': 'Baseline (Day 1; Week 0) and Day 252 (Week 36)', 'description': 'The SAS is an instrument that measures autonomic symptoms used for assessing autonomic neuropathies in clinical trials. The SAS scale evaluates the presence of symptoms and the degree of severity. The SAS consists of 11 questions in women and 12 questions in men. Each question has a Yes or No answer to symptoms occurring 6 months prior to investigational product (IP) administration. Questions answered with "Yes" are further rated by asking the participant how much each symptom is bothering him or her. Each answer is scored on a scale from 1 to 5 where 1 = not at all and 5 = a lot, and a total symptom impact score is determined. The SAS total impact score is the total of the scores from each question (11 for women and 12 for men). The minimum score is 0 and the maximum is 55 for women and 60 for men. A higher score indicates worse autonomic dysfunction.'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs)', 'timeFrame': 'Weeks 0 (Day 1), 2 (Day 14), 4 (Day 28), 8 (Day 56), 10 (Day 70), 12 (Day 84), 28 (Day 168), and 32 (Day 224)', 'description': 'Number of participants with clinically significant abnormal ECGs are reported.'}, {'measure': 'Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.'}, {'measure': 'Change From Baseline in C-reactive Protein Level to Week 12', 'timeFrame': 'Baseline (Day -7 to -1, inclusive) and Week 12', 'description': 'Change from baseline in C-reactive protein level to Week 12 is reported.'}, {'measure': 'Number of Participants With Injection Site Reactions', 'timeFrame': 'Day 1 through 41 weeks (maximum observed duration)', 'description': 'Number of participants with injection site reactions are reported.'}, {'measure': 'Number of Participants With Abnormal X-ray and/or Magnetic Resonance Imaging (MRI) of Large Joints', 'timeFrame': 'Baseline (Day -45 to -1) and Week 32', 'description': 'Number of participants with abnormal X-ray and/or MRI of large joints is reported.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Osteoarthritis'], 'conditions': ['Painful Osteoarthritis of the Knee']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D5680C00003&attachmentIdentifier=8e130b5d-6abf-4fdb-8ced-ef32e98cf47c&fileName=MEDI7352_Study_03_CSR_Synopsis_Redacted.pdf&versionIdentifier=', 'label': 'CSR Synopsis'}]}, 'descriptionModule': {'briefSummary': 'This is a Phase IIb randomised, double-blind, placebo-controlled, dose-response study in participants with painful osteoarthritis (OA) of the knee. The study will assess the safety and efficacy of multiple doses of MEDI7352 compared to placebo, as well as the pharmacokinetics, pharmacodynamics and immunogenicity of MEDI7352 in participants with moderate to severe chronic pain persistent for 3 months or more not adequately controlled by standard of care treatments.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Participants must understand the nature of the study and must give signed and dated written informed consent prior to the initiation of any study procedures, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n2. For participants participating in the optional genetic research, a separate signed and dated optional genetic research ICF must be provided prior to collection of samples for optional genetic research that supports the Genomics Initiative. If a participant declines to participate in the genetic research, this will have no influence on the ability of a participant to participate in the study.\n3. The participant should be willing and able to understand and comply with all protocol-specified restrictions and procedures and be able to use an electronic patient-reported outcome (ePRO) device as judged by the investigator.\n4. The participant must be considered likely to comply with the study protocol and to have a high probability of completing the study, as judged by the investigator.\n5. The participant must be willing and able to discontinue all analgesic therapy with nonsteroidal anti-inflammatory drugs (NSAID) or cyclooxygenase-2 (COX-2) inhibitors from the start of the washout period until the end of the FU period. This includes over-the-counter (OTC) pain medications and topical analgesics that contain an NSAID or COX-2 inhibitor.\n\nExclusion Criteria:\n\n1. Requires current treatment with another biologic therapeutic agent, disease-modifying antirheumatic drug (DMARD), or other immunosuppressants.\n2. Previously received any form of anti-nerve growth factor (NGF); received anti-tumour necrosis factors (TNFs) including but not limited to golimumab, certolizumab, infliximab, adalimumab, etanercept, or rituximab within 12 months prior to screening, or other biological DMARDs (including but not limited to abatacept, tocilizumab, and tofacitinib), or other immunosuppressants within 6 months prior to screening (with the exception of inhaled or topical corticosteroids).\n3. Currently receiving strong opioids for any indication.\n4. Participation in another clinical study with an IP or device within 60 days or 5 half-lives, whichever is longer, prior to screening.\n5. Plasma donation within 28 days of screening or any blood donation or blood loss \\> 500 mL within 2 months of screening.\n6. Previous allogeneic bone marrow or stem cell transplant.\n7. Received nonleukocyte-depleted whole blood transfusion within 120 days of the genetic research sample collection, if participating in the optional genetic research.\n8. Involvement in the planning and/or conduct of the study.'}, 'identificationModule': {'nctId': 'NCT04675034', 'acronym': 'BESPOKE', 'briefTitle': 'A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee', 'organization': {'class': 'INDUSTRY', 'fullName': 'AstraZeneca'}, 'officialTitle': 'A Randomised, Double-blind, Placebo-controlled, Dose-response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee', 'orgStudyIdInfo': {'id': 'D5680C00003'}, 'secondaryIdInfos': [{'id': '2020-003797-51', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MEDl7352 Dose 1', 'description': 'Participants received 6 doses of subcutaneous (SC) MEDl7352 Dose 1 injection once every 2 weeks (Q2W) during a 12-week parallel-group treatment period.', 'interventionNames': ['Drug: MEDI7352']}, {'type': 'EXPERIMENTAL', 'label': 'MEDl7352 Dose 2', 'description': 'Participants received 6 doses of SC MEDl7352 Dose 2 injection Q2W during a 12-week parallel-group treatment period.', 'interventionNames': ['Drug: MEDI7352']}, {'type': 'EXPERIMENTAL', 'label': 'MEDl7352 Dose 3', 'description': 'Participants received 6 doses of SC MEDl7352 Dose 3 injection Q2W during a 12-week parallel-group treatment period.', 'interventionNames': ['Drug: MEDI7352']}, {'type': 'EXPERIMENTAL', 'label': 'MEDl7352 Dose 4', 'description': 'Participants received 6 doses of SC MEDl7352 Dose 4 injection Q2W during a 12-week parallel-group treatment period.', 'interventionNames': ['Drug: MEDI7352']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Participants received 6 doses of SC placebo injection matched to MEDl7352 Q2W during a 12-week parallel-group treatment period.', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'MEDI7352', 'type': 'DRUG', 'description': 'Participants will receive SC injection of MEDI7352 as stated in arm description.', 'armGroupLabels': ['MEDl7352 Dose 1', 'MEDl7352 Dose 2', 'MEDl7352 Dose 3', 'MEDl7352 Dose 4']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Participants will receive SC injection of placebo as stated in arm description.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '2000', 'city': 'Frederiksberg', 'country': 'Denmark', 'facility': 'Research Site', 'geoPoint': {'lat': 55.67938, 'lon': 12.53463}}, {'zip': '10117', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Research Site', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '50708', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Research Site', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '18209', 'city': 'Bad Doberan', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 54.10712, 'lon': 11.90051}}, {'zip': '04107', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '80809', 'city': 'Munich', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'zip': '15-351', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '15-897', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '85-065', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '82-300', 'city': 'Elblag', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'zip': '81-338', 'city': 'Gdynia', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'zip': '90-302', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '20-607', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '61-113', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '24-100', 'city': 'Puławy', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 51.41655, 'lon': 21.96939}}, {'zip': '28-200', 'city': 'Staszów', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 50.56307, 'lon': 21.16593}}, {'zip': '87-100', 'city': 'Torun', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'zip': '00-874', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '22-400', 'city': 'Zamość', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 50.72314, 'lon': 23.25196}}, {'zip': '15006', 'city': 'A Coruña', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28034', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '29010', 'city': 'Málaga', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '08208', 'city': 'Sabadell', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'zip': '15702', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '15705', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '15706', 'city': 'Santiago de Compostela-Coruña', 'country': 'Spain', 'facility': 'Research Site'}, {'zip': '46010', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': 'NN18 9EZ', 'city': 'Corby', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 52.49637, 'lon': -0.68939}}, {'zip': 'EN3 4GS', 'city': 'Enfield', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.65147, 'lon': -0.08497}}, {'zip': 'G51 4TF', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'HP11 2QW', 'city': 'High Wycombe', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.62907, 'lon': -0.74934}}, {'zip': 'LS7 4SA', 'city': 'Leeds', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'EC2Y 8EA', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'CW9 7LS', 'city': 'Northwich', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.25882, 'lon': -2.52025}}, {'zip': 'HA6 2RN', 'city': 'Northwood', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.61162, 'lon': -0.42454}}, {'zip': 'BR5 3QG', 'city': 'Orpington', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.37457, 'lon': 0.09785}}, {'zip': 'PR2 9QB', 'city': 'Preston', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.76282, 'lon': -2.70452}}, {'zip': 'OL11 4AU', 'city': 'Rochdale', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.61766, 'lon': -2.1552}}, {'zip': 'M6 8HD', 'city': 'Salford', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.48771, 'lon': -2.29042}}, {'zip': 'BD18 3SA', 'city': 'Shipley', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.83333, 'lon': -1.76667}}]}, 'ipdSharingStatementModule': {'url': 'https://astrazenecagroup-dt.pharmacm.com/DT/Home', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.', 'ipdSharing': 'YES', 'description': 'Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.', 'accessCriteria': 'When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.\n\nSigned Data Sharing Agreement (non-negotiable contract for data accessors) must be In place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}